The potential for BTK inhibition in ITP was initially observed in patients with B‐cell malignancies complicated by ITP, in whom initiation of ibrutinib therapy led to high rates of ITP remission [68]. Here, BTK is linked to autoimmune thrombocytopenic purpura.